Royal jelly's most reliable effect is lowering markers of oxidative damage and raising antioxidant capacity. Moderate evidence supports relief of menopausal symptoms and modest cholesterol improvement, mainly when levels are unhealthy and at higher doses taken for over two months. Blood sugar and inflammation effects are inconsistent, long-life claims remain unproven, and a small but serious allergy risk persists. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Total cholesterol | <180 mg/dL | Primary lipid outcome with the most consistent trial benefit |
| LDL cholesterol | <100 mg/dL (lower if high-risk) | Tracks cardiovascular-relevant lipid response |
| HDL cholesterol | >50 mg/dL (women), >40 mg/dL (men) | Detects lipid-fraction shifts reported in some trials |
| Triglycerides | <90 mg/dL | Lipid fraction sometimes improved with royal jelly |
| Fasting blood glucose | 70–85 mg/dL | Glucose effect is subgroup-specific; needed to detect benefit and avoid over-lowering |
| HbA1c | <5.4% | Average blood sugar over ~3 months; checks durable glycemic effect |
| High-sensitivity C-reactive protein | <1.0 mg/L | Inflammation marker; trials show no significant pooled change, so flat values are expected |
| Blood pressure | <120/80 mmHg | Detects the mild blood-pressure-lowering effect, especially with antihypertensives |
| INR (if on anticoagulants) | Per therapeutic target | Detects the warfarin–royal jelly bleeding interaction |
Cadence: Baseline before first dose, at ~8 weeks, then every 3–6 months; more frequent blood-pressure or blood-sugar checks in the first 8 weeks for those on interacting medications